A Phase 1 Study of E7130 in Subjects With Solid Tumor
Latest Information Update: 07 Mar 2025
At a glance
- Drugs E-7130 (Primary)
- Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Eisai Co Ltd
Most Recent Events
- 05 Mar 2025 Status changed from active, no longer recruiting to completed.
- 05 Nov 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 05 Nov 2024 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2026.